Most Recent
Two units of US pharmaceutical giant Pfizer have filed a lawsuit seeking damages from Juno Pharmaceuticals for allegedly infringing the patent for post-operative pain drug Dynastat.
The Queensland Supreme Court judge has refused to transfer proceedings by villa owners against Clive Palmer's abandoned Sunshine Coast resort to the Federal Court, but has also rejected a separate bid by Palmer to shut down the case, which has been dormant for six years.
3A Composites has slammed the pleadings in a class action against it over allegedly combustible cladding, questioning whether the stated common issues are actually common to all group members.
The lead applicant in a class action over the Carwoola bushfire has been given the greenlight to go after CGU Insurance for loss and damage caused by the 2017 fire, which was allegedly sparked by the now insolvent Advanced Plumbing and Drains.
A former senior manager of Plutus Payroll played a "high level" role in a complex scheme that defrauded the Australian Taxation Office to the tune of $105 million, a court has heard, in a case involving one of the biggest revenue losses ever prosecuted.
The barrister leading an appeal seeking to revive Quinn Emanuel's fees for no service class action against AMP has criticised the approach taken in the landmark GetSwift ruling on competing class actions, saying it placed the court in the role of auctioneer and actually encouraged duplicative proceedings.
Bellamy's has lost its appeals court battle to limit the costs incurred by lawyers jointly running two shareholder class actions against the baby food maker.
A judge has signed off on a $40 million settlement reached in shareholder class action against Sirtex, including a $10 million cut for the funders, saying commission rates should reflect the risks taken by funders.
Facebook and Instagram have denied allegations they breached Australia's competition law when they terminated the accounts of a Melbourne-based startup, saying they were entitled to block the company from their platforms.
US biotechnology company Regeneron Pharmaceuticals has filed a Federal Court challenge after losing its opposition to a patent application by UK biopharmaceutical company Kymab for a method of producing an animal with part-human DNA.